AstraZeneca: new approval for Imfinzi in the USA
(CercleFinance.com) - AstraZeneca announced on Friday that the US FDA has approved the marketing of its Imfinzi immunotherapy for surgery-susceptible lung cancer.
The FDA approval covers the use of Imfinzi for the treatment of non-small cell cancer in combination with chemotherapy, before and after surgery.
The approval focuses on early stage disease (IIA-IIIB) in patients for whom no 'EGFR' or 'ALK' mutation could be identified.
According to the results of a study published last year in the scientific journal The New England Journal of Medicine, the drug reduced the risk of recurrence, disease progression or death by 32% compared to chemotherapy alone.
Lung cancer affects 2.4 million people every year, with 235,000 new cases occurring in the US.
Between 25% and 30% of non-small cell lung cancer cases are diagnosed early enough to benefit from surgery.
However, the majority of these patients usually suffer a relapse, with an estimated survival rate of between 36% and 46% at five years for stage II disease.
Following this announcement, AstraZeneca shares were down 0.1% on Friday morning on the London Stock Exchange, the victim of slight profit-taking after setting record after record in recent trading sessions.
Copyright (c) 2024 CercleFinance.com. All rights reserved.
The FDA approval covers the use of Imfinzi for the treatment of non-small cell cancer in combination with chemotherapy, before and after surgery.
The approval focuses on early stage disease (IIA-IIIB) in patients for whom no 'EGFR' or 'ALK' mutation could be identified.
According to the results of a study published last year in the scientific journal The New England Journal of Medicine, the drug reduced the risk of recurrence, disease progression or death by 32% compared to chemotherapy alone.
Lung cancer affects 2.4 million people every year, with 235,000 new cases occurring in the US.
Between 25% and 30% of non-small cell lung cancer cases are diagnosed early enough to benefit from surgery.
However, the majority of these patients usually suffer a relapse, with an estimated survival rate of between 36% and 46% at five years for stage II disease.
Following this announcement, AstraZeneca shares were down 0.1% on Friday morning on the London Stock Exchange, the victim of slight profit-taking after setting record after record in recent trading sessions.
Copyright (c) 2024 CercleFinance.com. All rights reserved.